Valeant Pharmaceuticals ( Valeant Pharmaceuticals )

Valeant Pharmaceuticals

Valeant Pharmaceuticals's picture

Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical company based in Laval, Quebec, Canada. Valeant develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. Valeant owns Bausch & Lomb, one of the largest manufacturers of contact lenses.

Valeant Pharmaceuticals press release, blog etc

12/29/2017 - 12:31 Valeant Announces Preliminary Resolution Of Allergan Shareholder Securities Litigation
12/22/2017 - 14:21 Bausch + Lomb Receives FDA Approval of LUMIFY - The Only Over-The-Counter Eye Drop With Low-Dose Brimonidine For The Treatment Of Eye Redness
12/20/2017 - 14:15 Valeant Completes Sale Of Sprout Pharmaceuticals Subsidiary To Former Shareholders Of Sprout Pharmaceuticals
12/18/2017 - 06:35 Bausch + Lomb Begins Distribution Of VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% To U.S. Wholesalers
12/07/2017 - 10:09 Valeant To Participate At The BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
12/03/2017 - 20:22 Valeant And One Of Its Subsidiaries Announce Upsize Of Cash Tender Offers To $1,500,000,000 Outstanding Principal Amount
11/21/2017 - 18:56 Valeant Announces Closing Of Add-On Secured Notes And Credit Agreement Amendment
11/21/2017 - 07:24 Valeant To Participate At The Evercore ISI Biopharma Catalyst/Deep Dive Conference
11/15/2017 - 08:57 First Sponsored Contact Lens Recycling Program Collects More Than 7,000 lbs. of Waste
11/14/2017 - 16:36 Valeant Announces Pricing Of Private Offering Of Add-On Secured Notes
11/14/2017 - 09:01 Ortho Dermatologics Announces Aspire Higher Scholarship Honorees
11/13/2017 - 05:42 Valeant Announces Launch of Private Offering of Add-On Secured Notes
11/10/2017 - 06:31 Valeant Pharmaceuticals Completes Sale of Obagi Medical Products Business to Haitong International Zhongua Finance Acquisition Fund I, L.P.
11/08/2017 - 15:29 Valeant To Participate At The Stifel 2017 Healthcare Conference
11/06/2017 - 13:17 Valeant Agrees To Sell Sprout Pharmaceuticals Subsidiary To Former Shareholders Of Sprout Pharmaceuticals
11/02/2017 - 14:02 Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-118, Novel Plaque Psoriasis Treatment
11/02/2017 - 11:57 Bausch + Lomb And Nicox Announce FDA Approval Of VYZULTA (latanoprostene Bunod Ophthalmic Solution), 0.024%
10/31/2017 - 12:47 Valeant Will Reduce Debt By Additional $125 Million